Centogene explores strategic alternatives

Cambridge, mass. and rostock, germany and berlin, feb. 28, 2024 (globe newswire) -- centogene n.v. (nasdaq: cntg) (the “company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that the company has decided to explore a range of strategic alternatives focused on sustainable long-term value creation for the benefit of its stakeholders.
CNTG Ratings Summary
CNTG Quant Ranking